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Background
Soluble guanylate cyclase (sGC) is the signal transduction
enzyme most responsible for mediating the effects of
nitric oxide by producing cyclic guanosine monophos-
phate (cGMP) from guanosine triphosphate (GTP). NO-
cGMP signaling is vital to proper cardiovascular function.
Deficiencies in the production of either NO or cGMP con-
tribute to cardiovascular disorders. Therapies designed to
increase in vivo NO levels (such as organic nitrates) have
well documented clinical limitations due to drug toler-
ance. Recently, a variety of NO-independent small mole-
cule activators of sGC have been reported that activate
nearly or as well as NO and have promising clinical activ-
ities. Previous results from our lab have shown that the
secreted matrix protein thrombospondin-1 (TSP-1) binds
to CD47 and potently inhibits NO stimulation of sGC.
Results
Here we show that TSP-1 signaling via CD47 also inhibits
sGC stimulation by NO-independent sGC stimulating
small molecules. Pretreatment of both porcine vascular
smooth muscle cells (VSMCs) and washed human plate-
lets with TSP-1 (1 μg/ml) significantly inhibited the abil-
ity of the heme dependent stimulators YC-1 (100 μM),
BAY 41-2272 (10 μM), and heme-independent activator
meso-porphyrin IX (10 μM) to elevate cGMP levels. TSP-
1 pretreatment also completely inhibited the ability of
these agents to delay thrombin induced aggregation of
washed human platelets. sGC stimulating agents also
failed to inhibit contraction of porcine VSMCs embedded
in a collagen gel pretreated with TSP-1.
Conclusion
This work demonstrates that sGC stimulation by NO
independent sGC stimulators is greatly diminished in the
presence of TSP-1/CD47 signaling. This data coupled with
the reported increases in TSP-1 with age, diabetes,
ischemia reperfusion, and atherosclerosis implies that the
therapeutic potential of NO-independent sGC stimulat-
ing drugs could be compromised in disease states with ele-
vated TSP-1/CD47 signaling.
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